

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities and Exchange Act of 1934

Date of report (Date of earliest event reported): December 21, 2000

VERTEX PHARMACEUTICALS INCORPORATED

(Exact name of registrant as specified in its charter)

Massachusetts

(State of incorporation)

000-19319

(Commission File No.)

04-3039129

(IRS Employer Identification No.)

130 Waverly Street

Cambridge, MA 02139

(Address of principal executive offices and zip code)

Registrant's telephone number, including area code: (617) 577-6000

Item 5. OTHER EVENTS

Richard H. Aldrich has resigned his position as Senior Vice President and Chief Business Officer of Vertex Pharmaceuticals Incorporated. Mr. Aldrich will continue to have a role at Vertex, reporting to Joshua Boger, Ph.D., Chairman and CEO, on issues of strategy, business development and collaborations.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

VERTEX PHARMACEUTICALS INCORPORATED

Dated: December 21, 2000

By: /s/ Joshua S. Boger

Joshua S. Boger
CEO